Cue Biopharma share price today

(CUE)

Cue Biopharma share price is $1.01 & ₹86.05 as on 25 Dec 2024, 2.30 'hrs' IST

$1.01

▲

-0.03

(-2.88%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Cue Biopharma share price in Dollar and Rupees. Guide to invest in Cue Biopharma from India. Also see the sentimental analysis on Indian investors investing in Cue Biopharma. Get details on the Indian mutual funds that are investing in Cue Biopharma. Get Analyst recommendations and forecasts along with all the Cue Biopharma's financials.

Cue Biopharma share price movements

Today's Low: $0.98
Today's High: $1.06
$1.01
2.95%
Downside
Day's Volatility :7.53%
Upside
4.72%
52 Weeks Low: $0.45
52 Weeks High: $3.20
$1.01
55.45%
Downside
52 Weeks Volatility :85.94%
Upside
68.44%

Cue Biopharma Returns

Period	Cue Biopharma Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	122.42%	-9.0%	0.0%
6 Months	-27.86%	-4.6%	0.0%
1 Year	-65.05%	3.0%	0.0%
3 Years	-91.51%	0.0%	-21.1%

Cue Biopharma Key Statistics

in dollars & INR

Previous Close	$1.04
Open	$1.0
Today's High	$1.06
Today's Low	$0.9802
Market Capitalization	$64.0M
Today's Volume	$139.3K
52 Week High	$3.2
52 Week Low	$0.45
Revenue TTM	$8.3M
EBITDA	$-47.7M
Earnings Per Share (EPS)	$-0.91
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-138.87%

How to invest in Cue Biopharma from India?

It is very easy for Indian residents to invest directly in Cue Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cue Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cue Biopharma or CUE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cue Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cue Biopharma shares which would translate to 0.844 fractional shares of Cue Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cue Biopharma, in just a few clicks!

Returns in Cue Biopharma for Indian investors in Rupees

Investment Value

₹1,00,000

Cue Biopharma investment value today

Current value as on today

₹37,187

Returns

₹62,813

(-62.81%)

Returns from Cue Biopharma Stock

₹65,052 (-65.05%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Cue Biopharma

-45%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Cue Biopharma on INDmoney from India has reduced in the last 30 days as on Dec 26, 2024. -45% less investors are searching Cue Biopharma in the last 30 days versus the previous period.

Global Institutional Holdings in Cue Biopharma

Bleichroeder LP
7.89%
Slate Path Capital LP
3.79%
Vanguard Group Inc
3.21%
BlackRock Inc
1.19%
Geode Capital Management, LLC
0.80%
Robertson Stephens Wealth Management, LLC
0.76%

Analyst Recommendation on Cue Biopharma

Buy

88%Buy

11%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Cue Biopharma(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cue Biopharma

What analysts predicted

Upside of 256.44%

Current:

$1.01

Target:

$3.60

Insights on Cue Biopharma

Price Movement
In the last 3 months, CUE stock has moved up by 122.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 1.71M → 3.33M (in $), with an average increase of 27.9% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -13.43M → -8.66M (in $), with an average increase of 15.9% per quarter
CUE vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.2% return, outperforming this stock by 94.6%
CUE vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 117.1%
Price to Sales
ForCUE every $1 of sales, investors are willing to pay $5.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.7 for every $1 of sales.

Cue Biopharma Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.1M	-
Net Income	$-39.0M	↑ 67.77%
Net Profit Margin	-3.4K%	-

	FY19	Y/Y Change
Revenue	$3.5M	↑ 202.64%
Net Income	$-36.7M	↓ 5.86%
Net Profit Margin	-1.1K%	↑ 2350.28%

	FY20	Y/Y Change
Revenue	$3.2M	↓ 8.78%
Net Income	$-44.8M	↑ 22.04%
Net Profit Margin	-1.4K%	↓ 358.54%

	FY21	Y/Y Change
Revenue	$14.9M	↑ 373.68%
Net Income	$-44.2M	↓ 1.39%
Net Profit Margin	-295.56%	↑ 1124.23%

	FY22	Y/Y Change
Revenue	$1.2M	↓ 91.67%
Net Income	$-52.8M	↑ 19.55%
Net Profit Margin	-4.2K%	↓ 3944.31%

	FY23	Y/Y Change
Revenue	$5.5M	↑ 340.88%
Net Income	$-50.7M	↓ 3.91%
Net Profit Margin	-924.1%	↑ 3315.77%

	Q2 FY23	Q/Q Change
Revenue	$1.4M	↑ 639.04%
Net Income	$-13.2M	↓ 0.17%
Net Profit Margin	-954.05%	↑ 6109.05%

	Q3 FY23	Q/Q Change
Revenue	$2.1M	↑ 51.95%
Net Income	$-11.0M	↓ 16.53%
Net Profit Margin	-524.05%	↑ 430.0%

	Q4 FY23	Q/Q Change
Revenue	$1.8M	↓ 13.29%
Net Income	$-13.4M	↑ 22.07%
Net Profit Margin	-737.73%	↓ 213.68%

	Q1 FY24	Q/Q Change
Revenue	$1.7M	↓ 5.71%
Net Income	$-12.3M	↓ 8.09%
Net Profit Margin	-719.1%	↑ 18.63%

	Q2 FY24	Q/Q Change
Revenue	$2.7M	↑ 54.8%
Net Income	$-10.2M	↓ 17.62%
Net Profit Margin	-382.66%	↑ 336.44%

	Q3 FY24	Q/Q Change
Revenue	$3.3M	↑ 25.51%
Net Income	$-8.7M	↓ 14.86%
Net Profit Margin	-259.59%	↑ 123.07%

	FY18	Y/Y Change
Profit	$1.1M	↓ 106.05%

	FY19	Y/Y Change
Profit	$3.5M	↑ 202.64%

	FY20	Y/Y Change
Profit	$-30.4M	↓ 978.87%

	FY21	Y/Y Change
Profit	$14.9M	↓ 149.16%

	FY22	Y/Y Change
Profit	$-560.8K	↓ 103.75%

	FY23	Y/Y Change
Profit	$-32.6M	↑ 5714.08%

	Q2 FY23	Q/Q Change
Profit	$534.0K	↓ 177.06%

	Q3 FY23	Q/Q Change
Profit	$1.2M	↑ 132.77%

	Q4 FY23	Q/Q Change
Profit	$970.0K	↓ 21.96%

	Q1 FY24	Q/Q Change
Profit	$868.0K	↓ 10.52%

	Q2 FY24	Q/Q Change
Profit	$-6.9M	↓ 891.71%

	Q3 FY24	Q/Q Change
Profit	$3.3M	↓ 148.54%

	FY18	Y/Y Change
Operating Cash Flow	$-26.4M	↑ 116.63%
Investing Cash Flow	$-20.4M	↑ 1589.18%
Financing Cash Flow	$4.2M	↓ 93.26%

	FY19	Y/Y Change
Operating Cash Flow	$-30.8M	↑ 16.61%
Investing Cash Flow	$3.4M	↓ 116.93%
Financing Cash Flow	$50.8M	↑ 1114.53%

	FY20	Y/Y Change
Operating Cash Flow	$-32.5M	↑ 5.51%
Investing Cash Flow	$4.5M	↑ 29.27%
Financing Cash Flow	$58.6M	↑ 15.41%

	FY21	Y/Y Change
Operating Cash Flow	$-38.8M	↑ 19.52%
Investing Cash Flow	$9.1M	↑ 104.42%
Financing Cash Flow	$19.2M	↓ 67.19%

	FY22	Y/Y Change
Operating Cash Flow	$-41.8M	↑ 7.64%
Investing Cash Flow	$-24.6M	↓ 370.19%
Financing Cash Flow	$53.7M	↑ 178.99%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-10.4M	↓ 4.26%
Investing Cash Flow	$5.0M	↓ 66.67%
Financing Cash Flow	$2.1M	↑ 441.49%

Cue Biopharma Technicals Summary

Sell

Neutral

Buy

Cue Biopharma is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cue Biopharma Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cue Biopharma Inc	-7.34%	-27.86%	-65.05%	-91.51%	-93.66%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-3.72%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cue Biopharma Inc	NA	NA	NA	-0.75	-1.39	-0.52	NA	0.79
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cue Biopharma Inc	Buy	$64.0M	-93.66%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Cue Biopharma

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Organization	Cue Biopharma
Employees	53
CEO	Mr. Daniel R. Passeri J.D., M.Sc.
Industry	Health Technology

Management People of Cue Biopharma

Name	Title
Mr. Daniel R. Passeri J.D., M.Sc.	CEO & Director
Dr. Anish Suri Ph.D.	President & Chief Scientific Officer
Dr. Ronald D. Seidel III, Ph.D.	Co-Founder
Dr. Rodolfo J. Chaparro Ph.D.	Co-Founder & Senior Advisor
Dr. Steven C. Almo Ph.D.	Co-Founder and Chairman of Scientific & Clinical Advisory Board
Mr. Colin G. Sandercock J.D., MSE	Senior VP, General Counsel & Secretary
Dr. Matteo Levisetti M.D.	Chief Medical Officer
Ms. Lucinda Warren	Chief Business Officer

Important FAQs about investing in Cue Biopharma from India :

What is Cue Biopharma share price today?

Cue Biopharma share price today stands at $1.01, Open: $1.00 ; Previous Close: $1.04 ; High: $1.06 ; Low: $0.98 ; 52 Week High: $3.20 ; 52 Week Low: $0.45. The stock opens at $1.00, after a previous close of $1.04. The stock reached a daily high of $1.06 and a low of $0.98, with a 52-week high of $3.20 and a 52-week low of $0.45.

Can Indians buy Cue Biopharma shares?

Yes, Indians can invest in the Cue Biopharma (CUE) from India.

With INDmoney, you can buy Cue Biopharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cue Biopharma at zero transaction cost.

How can I buy Cue Biopharma shares from India?

It is very easy to buy Cue Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cue Biopharma be purchased?

Yes, you can buy fractional shares of Cue Biopharma with INDmoney app.

What are the documents required to start investing in Cue Biopharma stocks?

To start investing in Cue Biopharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.